Adriana Manzi

Adriana has over 30 years’ of experience developing and managing the implementation of CMC strategies for small molecules, recombinant, fusion and transgenic proteins, cell-based therapies, biosimilars, analytical method development and validation. As a co-founder of Atheln, she has led the CMC efforts for many virtual companies through their first successful IND filing, interacted with regulators in the US and EU, advised international investors, provided technical opinions to law firms and participated in global due diligence efforts. Prior to consulting Adriana was at Baxter, Nextran, Cytel, and UC San Diego.